IE
ZNTL icon

Israel Englander’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Israel Englander’s Portfolio ZNTL Stock Details ZNTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.22M Sell
664,281
-625,541
-48% -$2.5M ﹤0.01% 3398
2026
Q1 		$3.02M Buy
1,289,822
+616,693
+92% +$1.59M ﹤0.01% 3455
2025
Q4 		$909K Sell
673,129
-229,392
-25% -$334K ﹤0.01% 4551
2025
Q3 		$1.36M Sell
902,521
-2,574,287
-74% -$3.86M ﹤0.01% 4374
2025
Q2 		$4.03M Buy
3,476,808
+407,294
+13% +$537K ﹤0.01% 3210
2025
Q1 		$4.88M Buy
3,069,514
+2,111,951
+221% +$4.55M ﹤0.01% 2888
2024
Q4 		$2.9M Buy
957,563
+71,477
+8% +$234K ﹤0.01% 3336
2024
Q3 		$3.26M Buy
886,086
+493,478
+126% +$1.79M ﹤0.01% 3225
2024
Q2 		$1.61M Buy
392,608
+146,286
+59% +$1.63M ﹤0.01% 3725
2024
Q1 		$3.88M Buy
246,322
+215,627
+702% +$2.97M ﹤0.01% 3128
2023
Q4 		$465K Sell
30,695
-416,225
-93% -$6.07M ﹤0.01% 4687
2023
Q3 		$8.97M Buy
446,920
+258,600
+137% +$6.56M ﹤0.01% 2145
2023
Q2 		$5.31M Buy
188,320
+158,926
+541% +$3.81M ﹤0.01% 2628
2023
Q1 		$506K Sell
29,394
-2,792
-9% -$56.5K ﹤0.01% 4596
2022
Q4 		$648K Sell
32,186
-68,486
-68% -$1.47M ﹤0.01% 4543
2022
Q3 		$2.18M Buy
+100,672
New +$2.75M ﹤0.01% 3665
2022
Q1 		– Sell
-35,966
Closed -$1.94M – 7584
2021
Q4 		$3.02M Buy
+35,966
New +$2.78M ﹤0.01% 3376
2021
Q3 		– Sell
-26,368
Closed -$1.4M – 7331
2021
Q2 		$1.4M Sell
26,368
-101,861
-79% -$5.46M ﹤0.01% 4330
2021
Q1 		$5.56M Buy
+128,229
New +$5.52M ﹤0.01% 2453

Other funds holding ZNTL

5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Israel Englander's ZNTL Position: Q2 2026 in Review

Israel Englander reduced its Zentalis Pharmaceuticals (ZNTL) stake by 48% in Q2 2026, selling an estimated $2.5M and leaving 664,281 shares worth $3.22M. The position accounts for ﹤0.01% of the portfolio, ranked #3398.

Israel Englander first reported a position in ZNTL in Q1 2021 and has held it in 19 quarters since. The position peaked at $8.97M in Q3 2023. 113 funds tracked by Wall St. Rank hold ZNTL as of Q2 2026.

  • Israel Englander held 664,281 shares of Zentalis Pharmaceuticals worth $3.22M as of Q2 2026.
  • Israel Englander sold 625,541 Zentalis Pharmaceuticals shares in Q2 2026, an estimated $2.5M.
  • Zentalis Pharmaceuticals made up ﹤0.01% of Israel Englander's portfolio in Q2 2026, its #3398 holding.
  • Israel Englander first reported a position in Zentalis Pharmaceuticals in Q1 2021 and has held it in 19 quarters since.
  • Israel Englander's Zentalis Pharmaceuticals position peaked at $8.97M in Q3 2023.
  • 113 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q2 2026.

Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.